# US 2018/0021259 A1 · Dye-stabilized nanoparticles and methods of their manufacture and therapeutic use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021259 A1
- Document ID: US20180021259A1
- Status: Published application
- Kind: A1
- Application number: 15/549,985
- Filed: 2016-02-09
- Published: 2018-01-25
- Earliest claimed: 2015-02-10
- Assignees: Memorial Sloan Kettering Cancer Center
- Applicants: Memorial Sloan Kettering Cancer Center
- Inventors: Daniel A. HELLER; Yosef SHAMAY
- Web page: https://patentgrep.com/patent/US20180021259A1

## CPC

- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1694: {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/4166: having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/42: Oxazoles
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 49/0034: {Indocyanine green, i.e. ICG, cardiogreen}
- A61K 49/0093: {Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle}
- G16B 15/30: Drug targeting using structural data; Docking or binding prediction
- A61K 9/1682: {Processes}
- G16B 15/00: ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
- G16C 20/50: Molecular design, e.g. of drugs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16C: COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE

## Abstract

Described herein are nanoparticles which are largely made of (e.g., 90 wt. %) hydrophobic drugs and are stabilized by water soluble dyes. The nanoparticles can range in size from 30 nm to 150 nm and have highly negative surface charge (e.g., −55 mV). These nanoparticles are highly soluble in water, stable for days in PBS buffer and can be easily lyophilzed and reconstituted in water. Using quantitative self-assembly prediction calculations, topochemical molecular descriptors were identified and validated as highly predictive indicators of nano-assembly, nanoparticle size, and drug loading. The resulting nanoparticles selectively targeted kinase inhibitors to caveolin-1-expressing human colon cancer and autochthonous liver cancer models to yield striking therapeutic effects while avoiding pERK inhibition in healthy skin. The nanoparticles exhibited remarkable anti-tumor efficacy in vitro and in vivo in models of hepatocellular carcinoma.

## Claims

### Claim 1

A dye-stabilized nanoparticle composition comprising
at least about 80 wt. % of one or more hydrophobic drugs; and
one or more sulfate-containing indocyanine dyes;
wherein the composition is in the form of nanoparticles having an intensity-weighted average diameter as determined by dynamic light scattering within a range from 30 nm to 150 nm.

### Claim 2 (depends on 1)

The dye-stabilized nanoparticle composition of claim 1, wherein the composition comprises at least 80 wt. % of the one or more hydrophobic drugs.

### Claim 3 (depends on 1)

The dye-stabilized nanoparticle composition of claim 1, wherein the composition comprises about 5 wt. % to about 20 wt. % of the one or more sulfate-containing indocyanine dyes.

### Claim 4 (depends on 1)

The dye-stabilized nanoparticle composition of claim 1, wherein the an intensity-weighted average diameter of the nanoparticles is within a range from 40 nm to 100 nm.

### Claim at position 5

5-6. (canceled)

### Claim 7 (depends on 1)

The dye-stabilized nanoparticle composition of claim 1, wherein the one or more hydrophobic drugs comprise a fluorine covalently bound to each of the one or more hydrophobic drugs.

### Claim 8 (depends on 1)

The dye-stabilized nanoparticle composition of claim 1, wherein the one or more hydrophobic drugs comprise one or more members selected from the group consisting of sorafenib, paclitaxel, docetaxel, MEK162, etoposide, lapatinib, nilotinib, crizotinib, fulvestrant, vemurafenib, bexorotene, camptothecin, Mek Azd, talazoparib, GSK214, luminespib, forskolin, ABT737, tacrolimus, BMS-777607, tanespimycin, everolimus, trametinib, navitoclax, celecoxib, avagacestat, dutasteride, enzalutamide, regorafenib, R04929097, valrubicin, and combinations of any two or more thereof.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The dye-stabilized nanoparticle composition of claim 1, wherein the one or more sulfate-containing indocyanine dyes comprise one or more members selected from the group consisting of IR783, IR806, IR820, IR125, and combinations of any two or more thereof.

### Claim 11 (depends on 1)

The dye-stabilized nanoparticle composition of claim 1, wherein the one or more sulfate-containing indocyanine dyes comprise IR783.

### Claim at position 11

12-14. (canceled)

### Claim 15 (depends on 1)

The dye-stabilized nanoparticle composition of claim 1, wherein the nanoparticles exhibit a zeta potential from −20 mV to −100 mV.

### Claim 16 (depends on 1)

The dye-stabilized nanoparticle composition of claim 1, wherein the one or more hydrophobic drugs are not covalently bonded to the one or more sulfate-containing indocyanine dyes.

### Claim at position 14

17-18. (canceled)

### Claim 19 (depends on 1)

A method of treating a disease or condition, the method comprising administering the dye-stabilized nanoparticle composition of claim 1 to a subject suffering from or susceptible to the disease or condition; wherein the disease or condition is selected from the group consisting of cancer, inflammatory disease, rheumatoid arthritis, inflammatory bowel disease, lupus, and age-related macular degeneration.

### Claim 20

(canceled)

### Claim 21 (depends on 19)

The method of claim 19, wherein the administered dye-stabilized nanoparticle composition obviate skin rashes.

### Claim 22 (depends on 19)

The method of claim 19, wherein the method further comprises irradiating the dye-stabilized nanoparticle composition subsequent to the administering.

### Claim 23 (depends on 1)

A method of making the dye-stabilized nanoparticle composition of claim 1, the method comprising
introducing a first solution into a second solution in a drop-wise manner while agitating the second solution;
wherein the first solution comprises the one or more hydrophobic drugs in a solvent, and the second solution is a buffered aqueous solution comprising the one or more sulfate-containing indocyanine dyes.

### Claim 24 (depends on 23)

The method of claim 23, wherein the solvent comprises DMSO, ethanol, or a combination thereof.

### Claim 25 (depends on 23)

The method of claim 23, wherein the second solution has a total concentration of about 1 mg/ml to about 3 mg/ml of the one or more sulfate-containing indocyanine dyes.

### Claim 26 (depends on 23)

The method of claim 23, wherein the method further comprises performing centrifugation and/or sonication to collect the formed nanoparticles.

### Claim 27

A method for predicting self-assembly of a dye-stabilized nanoparticle composition, the method comprising
providing a molecular structure of a drug;
generating, by a computer program a set of one or more molecular descriptors for the drug, wherein the set of molecular descriptors comprises one or more of (i), (ii), (iii), and (iv) as follows:
(i) a first molecular descriptor identifying a likelihood the drug will self-assemble with a dye to generate a dye-stabilized nanoparticle composition comprising the drug and the dye;
(ii) a second molecular descriptor identifying a maximal quantity of drug that can be loaded into a/the dye-stabilized nanoparticle composition comprising the drug and the dye;
(iii) a third molecular descriptor identifying hydrophobicity of the drug; and
(iv) a fourth molecular descriptor identifying a diameter of a/the dye-stabilized nanoparticle composition comprising the drug and the dye.

### Claim at position 24

28-37. (canceled)

### Claim 38 (depends on 1)

The dye-stabilized nanoparticle composition of claim 1, wherein the composition further comprises one or more members selected from the group consisting of IR775, IR780, or a combination thereof.

### Claim 39 (depends on 1)

The dye-stabilized nanoparticle composition of claim 1, wherein the composition exhibits a polydispersity index of about 0.05 to about 0.3.
